BioNTech

BioNTech SE is a <a href="/facts/Germany/paluuWBX">German</a> <a href="/facts/Multinational_corporation/qrMQSMTb">multinational</a> <a href="/facts/Biotechnology/8eFnI6FB">biotechnology</a> company headquartered in <a href="/facts/Mainz/vT0TxGjz">Mainz</a> that develops <a href="/facts/Immunotherapy/hgq3KQaJ">immunotherapies</a> and <a href="/facts/Vaccine/QcXzLug2">vaccines</a>, particularly for cancer and infectious diseases.
The company utilizes technology platforms including <a href="/facts/Messenger_RNA/oUL6qxQn">mRNA</a>-based therapies, targeted therapies, and <a href="/facts/Immunotherapy/hgq3KQaJ">immunomodulators</a>, to develop its treatments. BioNTech's pipeline includes several late-stage programs in <a href="/facts/Oncology/t2CUAEJQ">oncology</a> testing combination therapy approaches to improve treatment outcomes.
In the field of <a href="/facts/Infection/182XrncP">infectious diseases</a>, BioNTech, partnering with <a href="/facts/Pfizer/1ADDanWs">Pfizer</a>, developed <a href="/facts/Pfizer%25E2%2580%2593BioNTech_COVID-19_vaccine/T0AYCJ9p">Comirnaty</a>, the first approved mRNA-based vaccine, which was widely used during the <a href="/facts/COVID-19_pandemic/0xTsh7Ut">COVID-19 pandemic</a>.

BioNTech open-in-new

BioNTech